Von Hoff DD - Search Results

1

High-throughput RNAi screening identifies a role for TNK1 in growth and survival of pancreatic cancer cells.

Henderson MC, Gonzales IM, Arora S, Choudhary A, Trent JM, Von Hoff DD, Mousses S, Azorsa DO. Henderson MC, et al. Among authors: von hoff dd. Mol Cancer Res. 2011 Jun;9(6):724-32. doi: 10.1158/1541-7786.MCR-10-0436. Epub 2011 May 2. Mol Cancer Res. 2011. PMID: 21536687 Free PMC article.

2

Direct cloning of human neuroblastoma cells in soft agar culture.

Von Hoff DD, Casper J, Bradley E, Trent JM, Hodach A, Reichert C, Makuch R, Altman A. Von Hoff DD, et al. Cancer Res. 1980 Oct;40(10):3591-7. Cancer Res. 1980. PMID: 7002289

3

Cloning of human neuroblastoma cells in soft agar.

Casper JT, Trent JM, Von Hoff DD. Casper JT, et al. Among authors: von hoff dd. Prog Clin Biol Res. 1980;48:101-11. Prog Clin Biol Res. 1980. PMID: 7208513 No abstract available.

4

Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray.

Han H, Bearss DJ, Browne LW, Calaluce R, Nagle RB, Von Hoff DD. Han H, et al. Among authors: von hoff dd. Cancer Res. 2002 May 15;62(10):2890-6. Cancer Res. 2002. PMID: 12019169

5

The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer.

Rojanala S, Han H, Muñoz RM, Browne W, Nagle R, Von Hoff DD, Bearss DJ. Rojanala S, et al. Among authors: von hoff dd. Mol Cancer Ther. 2004 Apr;3(4):451-7. Mol Cancer Ther. 2004. PMID: 15078988

6

Targeting loss-of-function mutations in tumor-suppressor genes as a strategy for development of cancer therapeutic agents.

Wang H, Han H, Mousses S, Von Hoff DD. Wang H, et al. Among authors: von hoff dd. Semin Oncol. 2006 Aug;33(4):513-20. doi: 10.1053/j.seminoncol.2006.04.013. Semin Oncol. 2006. PMID: 16890805 Review.

7

Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells.

Wang H, Han H, Von Hoff DD. Wang H, et al. Among authors: von hoff dd. Cancer Res. 2006 Oct 1;66(19):9722-30. doi: 10.1158/0008-5472.CAN-05-4602. Cancer Res. 2006. PMID: 17018631

8

Identification of a novel inhibitor of urokinase-type plasminogen activator.

Zhu M, Gokhale VM, Szabo L, Munoz RM, Baek H, Bashyam S, Hurley LH, Von Hoff DD, Han H. Zhu M, et al. Among authors: von hoff dd. Mol Cancer Ther. 2007 Apr;6(4):1348-56. doi: 10.1158/1535-7163.MCT-06-0520. Mol Cancer Ther. 2007. PMID: 17431113

9

Adrenocortical carcinoma survival rates correlated to genomic copy number variants.

Stephan EA, Chung TH, Grant CS, Kim S, Von Hoff DD, Trent JM, Demeure MJ. Stephan EA, et al. Among authors: von hoff dd. Mol Cancer Ther. 2008 Feb;7(2):425-31. doi: 10.1158/1535-7163.MCT-07-0267. Mol Cancer Ther. 2008. PMID: 18281524

10

Gene expression profiling-based identification of cell-surface targets for developing multimeric ligands in pancreatic cancer.

Balagurunathan Y, Morse DL, Hostetter G, Shanmugam V, Stafford P, Shack S, Pearson J, Trissal M, Demeure MJ, Von Hoff DD, Hruby VJ, Gillies RJ, Han H. Balagurunathan Y, et al. Among authors: von hoff dd. Mol Cancer Ther. 2008 Sep;7(9):3071-80. doi: 10.1158/1535-7163.MCT-08-0402. Epub 2008 Sep 2. Mol Cancer Ther. 2008. PMID: 18765825 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

773 results

Search Page

Filters